Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, announced it has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna. The agreement covers preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU, a biologic therapy consisting of extracellular vesicles derived from bone marrow mesenchymal stromal cells. Phoenestra GmbH is a co-signatory to the agreement.
Preclinical studies of LK-ICU indicate an almost complete preservation of both diaphragm muscle fiber size and function, which are normally compromised by the use of mechanical ventilation. Extended weaning from mechanical ventilation, often resulting from ICU-acquired weakness, is estimated to impact the quality-of-life of hundreds of thousands of patients each year in the United States and Europe. By preserving diaphragm muscle integrity, LK-ICU could potentially reduce the duration of mechanical ventilation and improve patient outcomes.
The significance of this agreement lies in its potential to address a substantial unmet need in critical care. ICU-acquired weakness is a common complication of prolonged mechanical ventilation and is associated with increased morbidity, mortality, and healthcare costs. Current management relies primarily on supportive care and rehabilitation, with no approved therapies to prevent or treat the muscle wasting that occurs. If LK-ICU proves successful in clinical trials, it could become the first therapeutic option to preserve diaphragm function during ventilation, fundamentally changing how clinicians manage patients requiring respiratory support.
Leksum plans to start efforts under the agreement upon closing its Series A financing round. The planning phase is expected to last several months. The company intends to use European clinical data to support its U.S. regulatory path. For more details, click here.
In addition to LK-ICU, Leksum's pipeline includes therapies for skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs, including GLP-1s. This broader focus on acquired muscle myopathies positions Leksum in a growing market for muscle-preserving biologics. The global market for muscle-wasting therapies is expanding due to aging populations and rising rates of chronic diseases, and Leksum's approach could capture significant value if its therapies demonstrate efficacy.
For industry observers, the agreement with a prestigious institution like the Medical University of Vienna lends credibility to Leksum's technology and may facilitate patient enrollment and regulatory interactions in Europe. The involvement of Phoenestra GmbH, a Vienna-based company, suggests a collaborative effort to leverage local expertise and infrastructure. Successful completion of the Phase I/II trials could pave the way for partnerships with larger pharmaceutical companies or additional investment. As Leksum advances its pipeline, the outcomes of this trial will be closely watched by investors, clinicians, and patients alike.
